Joseph Franses, MD, PhD, is a skilled oncologist who focuses on gastrointestinal cancers, primarily hepatocellular carcinoma and biliary tract cancers. Dr. Franses is an expert in diagnosing and treating cancer and is known for his compassionate and individualized approach to patient care, taking the time to truly understand each patient's unique needs and concerns.
Dr. Franses is dedicated to improving the lives of his patients through both medical care and ongoing support. He works closely with a team of specialists to develop comprehensive treatment plans that are tailored to each patient's specific situation.
In addition to his clinical work, Dr. Franses is a physician-scientist who is committed to staying at the forefront of advancements in cancer treatment and uses this knowledge to provide the best possible care to his patients. He is actively involved in research that is investigating the tumor microenvironment and mechanisms of metastasis, focusing on how these features lead to de novo and acquired therapeutic resistance in gastrointestinal cancers. Dr. Franses’ work has been published in peer-reviewed journals like Nature Communications, Cancer Discovery, Gastroenterology, Annals of Surgery and more.
Complete Response to Immunotherapy in Patients With Hepatocellular Carcinoma.
Complete Response to Immunotherapy in Patients With Hepatocellular Carcinoma. JAMA Netw Open. 2025 Feb 03; 8(2):e2461735.
PMID: 39998829
Tumor cell-based liquid biopsy using high-throughput microfluidic enrichment of entire leukapheresis product.
Tumor cell-based liquid biopsy using high-throughput microfluidic enrichment of entire leukapheresis product. Nat Commun. 2025 01 02; 16(1):32.
PMID: 39746954
How to Predict Recurrence After Resection of Hepatocellular Carcinoma.
How to Predict Recurrence After Resection of Hepatocellular Carcinoma. Anticancer Res. 2025 Jan; 45(1):189-199.
PMID: 39740812
HCC spatial transcriptomic profiling reveals significant and potentially targetable cancer-endothelial interactions.
HCC spatial transcriptomic profiling reveals significant and potentially targetable cancer-endothelial interactions. Hepatol Commun. 2024 10 01; 8(10).
PMID: 39330965
Targeted therapies in hepatocellular carcinoma: past, present, and future.
Targeted therapies in hepatocellular carcinoma: past, present, and future. Front Oncol. 2024; 14:1432423.
PMID: 39267840
Spatially resolved immune drivers of HBV-associated HCC relapse.
Spatially resolved immune drivers of HBV-associated HCC relapse. Hepatology. 2025 May 01; 81(5):1394-1396.
PMID: 39106201
Hypofractionated Radiotherapy-Related Lymphopenia Is Associated With Worse Survival in Unresectable Intrahepatic Cholangiocarcinoma.
Hypofractionated Radiotherapy-Related Lymphopenia Is Associated With Worse Survival in Unresectable Intrahepatic Cholangiocarcinoma. Am J Clin Oncol. 2024 Aug 01; 47(8):373-382.
PMID: 38767086
Tumor cell-based liquid biopsy using high-throughput microfluidic enrichment of entire leukapheresis product.
Tumor cell-based liquid biopsy using high-throughput microfluidic enrichment of entire leukapheresis product. bioRxiv. 2024 Mar 14.
PMID: 38559183
Ultrasensitive Detection of Circulating LINE-1 ORF1p as a Specific Multicancer Biomarker.
Ultrasensitive Detection of Circulating LINE-1 ORF1p as a Specific Multicancer Biomarker. Cancer Discov. 2023 12 12; 13(12):2532-2547.
PMID: 37698949
Dysregulated Repeat Element Viral-like Immune Response in Hepatocellular Carcinoma.
Dysregulated Repeat Element Viral-like Immune Response in Hepatocellular Carcinoma. bioRxiv. 2023 Dec 05.
PMID: 38105940